ArticleBMC cancer2020
IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Increased IL- 36γ in visceral adipose tissue as a key mediator of obesity-driven inflammation in colon cancer.Journal of molecular medicine (Berlin, Germany) · 2025Article
- The differential role of IL-33 and IL-38 in prostate cancer, contradictory roles.Frontiers in immunology · 2025Review
- Dichotomous roles of IL-36 and IL-38 in cardiovascular disease.Frontiers in immunology · 2025Review
- Tertiary lymphoid structures in colorectal cancer.Annals of medicine · 2024Review
- Review
- IL-38 promotes the development of prostate cancer.Frontiers in immunology · 2024Article
- Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.Frontiers in immunology · 2024Article
- IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages.Cancer immunology, immunotherapy : CII · 2023Article
- New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review).Experimental and therapeutic medicine · 2023Review
- Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis.British journal of cancer · 2023Article
- The Pro-Tumor Biological Function of IL-36α Plays an Important Role in the Tumor Microenvironment of HCC.Cancer management and research · 2023Article
- Clinical implications of interleukins-31, 32, and 33 in gastric cancer.World journal of gastrointestinal oncology · 2022Article
- IL-36γ and IL-36Ra Reciprocally Regulate Colon Inflammation and Tumorigenesis by Modulating the Cell-Matrix Adhesion Network and Wnt Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- The Role of IL-37 and IL-38 in Colorectal Cancer.Frontiers in medicine · 2022Review
- IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore.Cellular and molecular life sciences : CMLS · 2021Review
- Novel mechanisms and clinical trial endpoints in intestinal fibrosis.Immunological reviews · 2021Review
- IL-36 in chronic inflammation and fibrosis - bridging the gap?The Journal of clinical investigation · 2021Review
- The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases.Frontiers in pharmacology · 2021Review
- The Role of IL-37 and IL-38 in Obstetrics Abnormalities.Frontiers in medicine · 2021Review
- The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsColorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear.
methodsCRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues.
resultsA significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α
conclusionIL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.